Semaglutide 2mg and the Wegovy Dose Ladder

Step 1: understanding why the numbers jump from 1.7 to 2.4

When people search for semaglutide 2mg, they're often mid-treatment and wondering why the dose they've read about online doesn't match what their pen says. It's a fair question. The licensed Wegovy schedule was designed around tolerability and efficacy data, and the steps chosen (0.25, 0.5, 1.0, 1.7, 2.4mg) reflect where clinical trial evidence supported both safety and meaningful effect. A 2mg increment was never part of that programme.

The jump from 1.7mg to 2.4mg can feel large on paper, but in practice many patients find the transition manageable once their gut has already adapted through the earlier steps. The GI effects that tend to accompany starting or increasing semaglutide (nausea, loose stools, fatigue) are usually at their most noticeable in the first week or two after a new dose, then settle. If they don't, that's a conversation to have with your prescriber before going further, not something to push through alone.

If you're still building familiarity with the earlier part of the schedule, the 1mg semaglutide step is covered separately. And if you're already approaching the upper end of the ladder, information on the 3mg semaglutide context may help you understand what higher-dose research is exploring. Anyone who wants a broader grounding in how semaglutide works as a medicine will find a full overview on our dedicated page, and for those specifically navigating the semaglutide 5mg dose, that step is covered in its own section too. The NHS semaglutide patient information sets out the full schedule clearly for anyone who wants to read the official source.

Step 2: what clinical evidence says about semaglutide at maintenance doses

The evidence base for Wegovy comes primarily from the STEP trial programme. STEP 1, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks at a 2.4mg weekly maintenance dose alongside lifestyle changes. The average weight reduction across participants was around 15%, compared with roughly 2.4% in the placebo group. These are averages from a controlled trial setting; individual results vary, and your prescriber will help you understand what a realistic outcome looks like for you.

It's worth knowing that this picture has evolved. The MHRA approved a higher 7.2mg maintenance dose in April 2026, initially requiring three 2.4mg pens weekly and then via a single dedicated pen. Trials at that dose reported average weight loss approaching 20.7% over 72 weeks. That approval was for adults with a BMI of 30 or above specifically. Whether any particular dose is appropriate is entirely a clinical decision; the existence of a higher option doesn't mean everyone should be aiming for it.

For a broader look at the cost landscape around Wegovy, the Wegovy cost context page covers what private treatment typically includes and why headline prices can be misleading.

Step 3: eligibility and what a prescriber looks at before any dose increase

Semaglutide for weight management is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Meeting those numbers is the starting point, not the whole picture.

Before any dose increase (including the move toward 2.4mg) a prescriber considers how well the current dose has been tolerated, whether weight loss is progressing appropriately, and whether anything in the patient's situation has changed. At nume, that review happens with every repeat order; a named prescriber reads through your details, not a system making automated decisions. The process is described on our about us page if you'd like to understand how the clinical team is structured.

Women using oral contraceptives alongside tirzepatide (Mounjaro, not semaglutide) are advised to add a barrier method during certain dose periods because of absorption effects. For semaglutide, NHS guidance notes there is no equivalent evidence of reduced pill effectiveness, though discussing contraception at your consultation is always worthwhile. Pregnancy, breastfeeding, and planning to conceive are situations where these medicines are not recommended; that applies at any dose level.

If you're considering starting treatment or want to explore whether you're suitable, the weight-loss treatment overview is a useful starting point, and our frequently asked questions page covers many of the practical queries people have before they begin.

Step 4: what to do if you have concerns mid-titration

Dose titration can feel uncertain, especially if you're navigating it through a service you've only recently joined. The question our prescribers hear often is something like: "I'm on 1.7mg and the nausea is still bad, do I still have to go up?" The answer is no, not automatically. The schedule is a clinical guide, not a rule that overrides how someone is actually feeling.

Side effects worth knowing about include the GI cluster (nausea, diarrhoea, constipation, reflux, and burping), headache, dizziness, and fatigue. Most are more pronounced at dose initiation or increase and tend to settle within a couple of weeks. Severe or persistent abdominal pain that radiates toward the back is a specific symptom to take seriously and seek medical attention for promptly, it can be a sign of pancreatitis, which the MHRA highlighted as an infrequent but potentially serious effect in its January 2026 Drug Safety Update for GLP-1 medicines. Suspected side effects can be reported at the MHRA's Yellow Card scheme.

If you're an existing patient with questions between orders, the contact page will reach the aftercare team, available seven days a week. For anyone who hasn't yet started and wants a prescriber to review their suitability, the right place is the consultation.